Asthma and COPD Drugs Market Size & Share, by Route of Administration (Oral, Inhaled, Intravenous, Subcutaneous); Distribution Channel (General Pharmacies, Hospital Pharmacies, Online Retailers); End-user (Asthma Patients, COPD Patients) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2024-2036

  • Report ID: 4116
  • Published Date: May 23, 2023
  • Report Format: PDF, PPT

Global Market Size, Forecast, and Trend Highlights Over 2024-2036

Asthma and COPD Drugs Market size was over USD 37 Billion in 2023 and is anticipated to exceed USD 97.9 Billion by the end of 2036, witnessing over 7.8% CAGR during the forecast period i.e., between 2024-2036. In the year 2024, the industry size of asthma and copd drugs is evaluated at USD 40.1 Billion. The market growth is due to the increasing prevalence of respiratory diseases.

The industry includes a variety of drugs, including bronchodilators, corticosteroids, combination therapies, and monoclonal antibodies. Furthermore, there have been surging investments in drugs, and therapy by competitors for the cure of diseases in order to have a competitive advantage.


Asthma and COPD Drugs Market
Get more information on this report: Request Free Sample PDF

Asthma and COPD Drugs Sector: Growth Drivers and Challenges

Growth Drivers

  • Rising prevalence of Asthma and COPD – The growth of the asthma and COPD drugs market is mainly driven by the increasing prevalence of COPD and asthma. For example, according to data stated by the World Health Organization (WHO) in 2019, asthma affected about 262 million population. Moreover, according to the fact stated by American Lung Organization in 2018, 99 million people in the United States have chronic bronchitis.
  • Development in Respiratory Diseases Therapeutics – There has been increasing in the launch of new products for the medication of chronic obstructive pulmonary diseases.  For example, AstraZenca, obtained European approval for "Trixeo Aerosphere" for the maintenance cure of COPD.
  • Increasing healthcare expenditure – Healthcare expenditure is on the rise globally, driven by factors such as population growth, aging, and the increasing burden of chronic diseases.

Challenges

  • Patent Expirations – Many of the blockbuster drugs used to treat respiratory diseases are coming off patent, which is leading to increased competition from generic drugs. This is likely to reduce the revenue of branded drugs and increase pressure on drug manufacturers to develop new and innovative drugs.
  • High cost of drugs
  • Adverse effects of drugs

Asthma and COPD Drugs Market: Key Insights

Base Year

2023

Forecast Year

2024-2036

CAGR

7.8%

Base Year Market Size (2023)

USD 37 Billion

Forecast Year Market Size (2036)

USD 97.9 Billion

Regional Scope

  • North America (U.S., and Canada)
  • Latin America (Mexico, Argentina, Rest of Latin America)
  • Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific)
  • Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of Middle East and Africa)
Get more information on this report: Request Free Sample PDF

Asthma and COPD Drugs Segmentation

End User (Asthma Patients, COPD Patients)

The COPD patients segment in the asthma and COPD drugs market is expected to witness around 60% growth rate through 2036. The growth of the segment can be accredited to the increasing prevalence of smoking.

Smoking is a major cause of COPD. While smoking rates have been declining in many parts of the world, there are still significant numbers of smokers, particularly in low- and middle-income countries. This is estimated to contribute to the increasing prevalence of COPD and drive demand for COPD drugs.

Distribution Channel (General Pharmacies, Online Retailers, Hospital Pharmacies)

The hospital pharmacies segment is estimated to gain the largest market share in the year 2036. Respiratory diseases such as asthma and COPD can require hospitalization, particularly in severe cases. The increasing prevalence of these conditions is likely to lead to an increase in hospitalizations, which is likely to drive demand for asthma and COPD drugs in hospital pharmacies.

According to a study of 2020, hospitalizations for asthma increased during the COVID-19 pandemic in several countries, across the globe. The study found that hospitalizations for asthma increased by 30-70% in these countries during the pandemic.

Our in-depth analysis of the global market includes the following segments:

           Distribution Channel

  • General Pharmacies
  • Hospital Pharmacies
  • Online Retailers

                    End User

  • Asthma Patients
  • COPD Patients

                   Route of Administration

  • Oral
  • Inhaled
  • Intravenous
  • Subcutaneous

Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.

Customize this Report

Asthma and COPD Drugs Industry - Regional Synopsis

North American Market Forecast

The asthma and COPD drugs market in the North America region, amongst all the other regions, are projected to hold the largest share between 2023 and 2036. The growing healthcare infrastructure in the North American region is able to provide the required treatment to the patients.

In addition, the governments and private insurance companies in North America generally provide favorable reimbursement policies for drugs dispensed through pharmacies and hospitals.

APAC Market Statistics

The Asia Pacific asthma and COPD drugs market is poised to register substantial growth rate during the forecast period. The aging population in the Asia Pacific region is growing rapidly, which is expected to lead to an increase in the number of people with respiratory diseases, particularly COPD.

Several governments in the region are taking initiatives to improve healthcare access and outcomes, including for respiratory diseases. For instance, the Chinese government launched the "Healthy China 2030" initiative, which aims to reduce the burden of chronic diseases, including respiratory diseases.

Research Nester
Asthma and COPD Drugs Market Size
Get more information on this report: Request Free Sample PDF

Companies dominating the Asthma and COPD Drugs Landscape

top-features-companies
    • GlaxoSmithKline plc.
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • AstraZeneca
    • Boehringer Ingelheim International GmbH
    • F. Hoffmann-La Roche Ltd.
    • Novartis AG
    • Sanofi
    • CHIESI Farmaceutici S.p.A.
    • Teva Pharmaceutical Industries Ltd.
    • Merck & Co., Inc.
    • Abbott

In the News

  • Dignity Health, and Propeller Health announced that they have integrated Propeller’s platform into Dignity Health’s electronic health record (EHR) system, which is fully implemented in seven communities served by Dignity Health physicians and clinics in Arizona and California.
  • True Corporation along with partners, Easy Asthma & COPD Clinics (EACC), a network of respiratory disease treatment clinics, and GlaxoSmithKline Thailand (GSK), a researcher and developer of innovative drugs and vaccines, launched “Telehealth Together” project to take care of patients suffering from respiratory diseases using True's health intelligent healthcare platform for telehealth services.

Author Credits:  Radhika Gupta, Shivam Bhutani


  • Report ID: 4116
  • Published Date: May 23, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

High prevalence and incidence of asthma and COPD, decreasing environmental air quality, and the presence of harmful gases and particles are the major factors driving the market growth.

The market size of asthma and COPD drugs is anticipated to attain a CAGR of ~10% over the forecast period, i.e., 2023-2035.

The side effects associated with respiratory drugs are estimated to be the growth hindering factor for the market expansion.

The market in the North America region is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.

The major players in the market are GlaxoSmithKline plc., AstraZeneca, Boehringer Ingelheim International GmbH, F. Hoffmann-La Roche Ltd., Novartis AG, Sanofi, CHIESI Farmaceutici S.p.A., Teva Pharmaceutical Industries Ltd., Merck & Co., Inc., Abbott, and others.

The company profiles are selected based on the revenues generated from the product segment, the geographical presence of the company which determines the revenue generating capacity as well as the new products being launched into the market by the company.

The market is segmented by route of administration, distribution channel, end user, and by region.

The COPD patients segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.
Asthma and COPD Drugs Market Report Scope
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying